48 results
Page 2 of 3
8-K
EX-99.1
1xwgji49
5 May 20
Fate Therapeutics Announces Changes to its Board of Directors
4:03pm
8-K
EX-99.1
evmpib5e9qqx
17 Jul 19
Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors
4:03pm
424B5
by79o1fvcru3svaaqswt
21 Sep 18
Prospectus supplement for primary offering
4:41pm
424B5
abocqk6g66qi4
20 Sep 18
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
av5mnzf1i5h yn1
6 Aug 18
Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress
4:10pm
8-K
j7pq33ry36zjc
18 May 18
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
4:05pm
8-K
EX-99.1
c7c389
18 May 18
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
4:05pm
8-K
EX-99.1
37e wxzpjpoukjww
17 Nov 14
Results of Operations and Financial Condition
12:00am